S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Harpoon Therapeutics Stock Forecast, Price & News

+0.98 (+5.35 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $19.29
50-Day Range
MA: $20.53
52-Week Range
Now: $19.29
Volume197,200 shs
Average Volume321,547 shs
Market Capitalization$489.58 million
P/E RatioN/A
Dividend YieldN/A
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:HARP
Year FoundedN/A



Sales & Book Value

Annual Sales$5.78 million
Book Value$3.82 per share


Net Income$-55,570,000.00
Net Margins-434.74%


Market Cap$489.58 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.49 out of 5 stars

Medical Sector

459th out of 1,962 stocks

Biological Products, Except Diagnostic Industry

61st out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.98 (+5.35 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

Is Harpoon Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Harpoon Therapeutics stock.
View analyst ratings for Harpoon Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Harpoon Therapeutics?

Wall Street analysts have given Harpoon Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Harpoon Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Harpoon Therapeutics

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) announced its earnings results on Wednesday, November, 4th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.04. The company earned $3.89 million during the quarter, compared to analysts' expectations of $4.60 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 68.32% and a negative net margin of 434.74%.
View Harpoon Therapeutics' earnings history

How has Harpoon Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HARP stock has increased by 47.6% and is now trading at $19.29.
View which stocks have been most impacted by COVID-19

What price target have analysts set for HARP?

7 Wall Street analysts have issued 1-year price objectives for Harpoon Therapeutics' stock. Their forecasts range from $25.00 to $38.00. On average, they anticipate Harpoon Therapeutics' share price to reach $31.57 in the next year. This suggests a possible upside of 63.7% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 66, Pay $749.11k)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 54, Pay $500.79k)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 56, Pay $538.42k)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 53)
  • Ms. Rachael Lester, VP of Corp. Devel.
  • Dr. Susan Dana Jones Ph.D., Sr. VP of Product Devel.
  • Dr. Che-Leung Law Ph.D., Sr. VP of Translational Medicine
  • Mr. Christopher Whitmore, VP of Fin. & Sec.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

4 employees have rated Harpoon Therapeutics CEO Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among Harpoon Therapeutics' employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Harpoon Therapeutics' key competitors?

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.38%), Avidity Partners Management LP (3.09%), Northern Trust Corp (0.62%), Bailard Inc. (0.54%), Charles Schwab Investment Management Inc. (0.46%) and Nuveen Asset Management LLC (0.39%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Bioventures 2014 LP Mpm, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Mark Chin, Natalie Sacks and Patrick Baeuerle.
View institutional ownership trends for Harpoon Therapeutics

Which institutional investors are selling Harpoon Therapeutics stock?

HARP stock was sold by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Russell Investments Group Ltd., Northern Trust Corp, Wells Fargo & Company MN, State of Wisconsin Investment Board, and Dimensional Fund Advisors LP. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Bioventures 2014 LP Mpm, Holger Wesche, and Natalie Sacks.
View insider buying and selling activity for Harpoon Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Harpoon Therapeutics stock?

HARP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., GSA Capital Partners LLP, Chartwell Investment Partners LLC, Nuveen Asset Management LLC, Pura Vida Investments LLC, Bailard Inc., and Charles Schwab Investment Management Inc.. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Georgia Erbez, and Gerald Phd Mcmahon.
View insider buying and selling activity for Harpoon Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $19.29.

How much money does Harpoon Therapeutics make?

Harpoon Therapeutics has a market capitalization of $489.58 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Harpoon Therapeutics have?

Harpoon Therapeutics employs 77 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is www.harpoontx.com.

Where are Harpoon Therapeutics' headquarters?

Harpoon Therapeutics is headquartered at 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]

This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.